Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers

被引:84
作者
Sader, HS [1 ]
Jones, RN
Andrade-Baiocchi, S
Biedenbach, DJ
机构
[1] Univ Fed Sao Paulo, Lab Especial Microbiol Clin, Div Infect Dis, Sao Paulo, Brazil
[2] JMI Labs, JONES Grp, N Liberty, IA USA
[3] Tufts Univ, Sch Med, Boston, MA 02111 USA
关键词
D O I
10.1016/S0732-8893(02)00469-8
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
As part of the Latin American arm of the SENTRY Antimicrobial Surveillance Program. 7,207 bacterial isolates collected consecutively from bloodstream infections (BSI) during the period of January 1997 through December 2000 were analyzed. Ten Latin American laboratories located in six countries participated in the study during each year. Antimicrobial susceptibility testing was performed using the reference NCCLS broth microdilution method. The most frequently isolated species were (n/%): Staphylococcus aureus (1,532/21.3%), Escherichia coli (1,239/17.2%), coagulase-negative Staphylococcus (1.002/13.9%), Klebsiella pneumoniae (664/9,2%), and Pseudomonas aeruginosa (470/6.5%). The prevalence of S. aureus as a cause of BSI increased from 20.5% in 1997 to 23.3% in 2000 (P = 0.011), but oxacillin-resistance rates remained relatively stable during this period (around 30%). Enterococci (216 isolates) showed low rates of resistance to both vancomycin (2.4%) and ampicillin (7.9%) and 72.7% of 289 Streptococcus pneumoniae isolates evaluated were susceptible to penicillin (MIC less than or equal to0.06 mug/mL). Resistance rates among Gram-negative bacilli were much higher than those reported in other regions evaluated in the SENTRY Program. The main antimicrobial resistance problems among these pathogens were the high prevalences of ESBL-producing E. coli (6.7%) and K. pneumoniae (47.3%). and carbapenem-resistance among P. aeruginosa (around 12%) and Acinetobacter spp. (around 10%). P. aeruginosa resistance rates to meropenem, piperacillin/tazobactam, amikacin, and ciprofloxacin showed a significant increase during the 4-year period evaluated. Resistance rates varied according to the country for several pathogen-antimicrobial combinations. In summary, resistance to most antimicrobial agents for a number of species implicated in bacteremia, especially among Gram-negative rods. has reached worrisome levels and continues to increase. (C) 2003 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:273 / 280
页数:8
相关论文
共 18 条
[1]   A FUNCTIONAL CLASSIFICATION SCHEME FOR BETA-LACTAMASES AND ITS CORRELATION WITH MOLECULAR-STRUCTURE [J].
BUSH, K ;
JACOBY, GA ;
MEDEIROS, AA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (06) :1211-1233
[2]   Detection of extended-spectrum beta-lactamase (ESBL)-producing strains by the Etest ESBL screen [J].
Cormican, MG ;
Marshall, SA ;
Jones, RN .
JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (08) :1880-1884
[3]   Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America [J].
Diekema, DJ ;
Pfaller, MA ;
Jones, RN ;
Doern, GV ;
Kugler, KC ;
Beach, ML ;
Sader, HS .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 13 (04) :257-271
[4]  
Diekema DJ, 1999, CLIN INFECT DIS, V29, P595, DOI 10.1086/598640
[5]   Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756 [J].
Fung-Tomc, JC ;
Minassian, B ;
Kolek, B ;
Huczko, E ;
Aleksunes, L ;
Stickle, T ;
Washo, T ;
Gradelski, E ;
Valera, L ;
Bonner, DP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (12) :3351-3356
[6]   Important and emerging β-lactamase-mediated resistances in hospital-based pathogens:: The amp C enzymes [J].
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1998, 31 (03) :461-466
[7]   Bacterial resistance: A worldwide problem [J].
Jones, RN ;
Pfaller, MA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1998, 31 (02) :379-388
[8]   EMERGING MULTIPLY RESISTANT ENTEROCOCCI AMONG CLINICAL ISOLATES .1. PREVALENCE DATA FROM 97 MEDICAL-CENTER SURVEILLANCE STUDY IN THE UNITED-STATES [J].
JONES, RN ;
SADER, HS ;
ERWIN, ME ;
ANDERSON, SC ;
ALDRIDGE, KA ;
ALLEN, S ;
ANHALT, J ;
APPELBAUM, P ;
ARRINGTON, KL ;
AYERS, L ;
BAKER, C ;
BEAVIS, K ;
BERGER, J ;
BERTHOLD, G ;
BIRNBAUM, M ;
BOYLE, J ;
BRECHER, S ;
BRECKENRIDGE, R ;
BROWN, W ;
BRUCKNER, D ;
CARROLL, K ;
CHAUDHARY, S ;
CLEARY, T ;
COCKERILL, F ;
COYLE, M ;
CRAWFORD, V ;
DALTON, H ;
DOERN, G ;
EDBERG, S ;
GELFAND, M ;
GERLACH, EH ;
GOODMAN, N ;
GORZYNSKI, E ;
GREEN, P ;
GROSCHEL, D ;
HANFF, P ;
HANNA, B ;
HARRELL, L ;
HAUGEN, T ;
HEAGREY, M ;
HUMPHRIES, J ;
ISENBERG, H ;
JENKINS, S ;
JONES, E ;
JORGENSEN, J ;
KAUFFMAN, C ;
KEISER, J ;
KOCKA, F ;
KOMINOS, S ;
LEVISON, M .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 21 (02) :85-93
[9]  
National Committee for Clinical Laboratory Standards (NCCLS), 2002, M7A5 NCCLS
[10]  
[NCCLS] National Committee for Clinical Laboratory Standards, 2002, M100S12 NCCLS